Real-World Outcomes of Targeted Therapies in Psoriatic Arthritis: Effectiveness, Persistence, Safety, Associated Factors, and Residual Unmet Needs

Targeted therapies have expanded treatment options for psoriatic arthritis (PsA), but clinical response, treatment continuation, and patient-perceived recovery may diverge in routine care. This review synthesized observational reports published between 1 January 2005 and 21 August 2026, distinguishing effectiveness, persistence, safety, outcome-associated factors, and residual burden. The available evidence comprised 64 publications, including 14 BIRRA reports. Synthesis retained outcome-specific definitions, analysis populations, and potential cohort overlap. Clinical and patient-reported improvements frequently coexisted with target nonattainment or persistent symptoms, although residual symptoms could not consistently be attributed to active inflammation. No synthesis met the review’s requirement for at least three sufficiently comparable independent cohorts. Two exploratory IL-17 inhibitor analyses estimated 12-month persistence at 74.9% (95% CI 17.8–95.3%) and the female-versus-male discontinuation hazard ratio at 1.89 (95% CI 0.10–37.32). These estimates were too imprecise for clinical prediction or treatment ranking. Safety comparisons were restricted by differences in exposure, ascertainment, and denominators. Associations involving sex, obesity, disease burden, and previous treatment were context dependent. Missing original search and screening records and incomplete risk-of-bias adjudication materially limit reproducibility and confidence. The review’s contribution is an integrated interpretation of distinct treatment outcomes rather than a therapeutic hierarchy. Molecular profiling offers complementary research directions but does not establish validated treatment-selection biomarkers within this evidence base.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-19
DOI
https://doi.org/10.3390/ijms272210415
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-World Outcomes of Targeted Therapies in Psoriatic Arthritis: Effectiveness, Persistence, Safety, Associated Factors, and Residual Unmet Needs

Alarico Ariani, Filippo Messina, Valerio Cipolloni, Cristina Clara Macía Villa et al.
International Journal of Molecular Sciences
Spondyloarthritis Studies and Treatments
article

Real-World Outcomes of Targeted Therapies in Psoriatic Arthritis: Effectiveness, Persistence, Safety, Associated Factors, and Residual Unmet Needs

Alarico Ariani, Filippo Messina, Valerio Cipolloni, Cristina Clara Macía Villa, María Ángeles Puche-Larrubia, Alessandro Conforti, Raoul Saggini, Rosa Grazia Bellomo
article en

Abstract

Targeted therapies have expanded treatment options for psoriatic arthritis (PsA), but clinical response, treatment continuation, and patient-perceived recovery may diverge in routine care. This review synthesized observational reports published between 1 January 2005 and 21 August 2026, distinguishing effectiveness, persistence, safety, outcome-associated factors, and residual burden. The available evidence comprised 64 publications, including 14 BIRRA reports. Synthesis retained outcome-specific definitions, analysis populations, and potential cohort overlap. Clinical and patient-reported improvements frequently coexisted with target nonattainment or persistent symptoms, although residual symptoms could not consistently be attributed to active inflammation. No synthesis met the review’s requirement for at least three sufficiently comparable independent cohorts. Two exploratory IL-17 inhibitor analyses estimated 12-month persistence at 74.9% (95% CI 17.8–95.3%) and the female-versus-male discontinuation hazard ratio at 1.89 (95% CI 0.10–37.32). These estimates were too imprecise for clinical prediction or treatment ranking. Safety comparisons were restricted by differences in exposure, ascertainment, and denominators. Associations involving sex, obesity, disease burden, and previous treatment were context dependent. Missing original search and screening records and incomplete risk-of-bias adjudication materially limit reproducibility and confidence. The review’s contribution is an integrated interpretation of distinct treatment outcomes rather than a therapeutic hierarchy. Molecular profiling offers complementary research directions but does not establish validated treatment-selection biomarkers within this evidence base.

International Journal of Molecular SciencesVol. 27(22)
Università degli Studi eCampus (IT), University of Campania "Luigi Vanvitelli" (IT), ASL Roma (IT), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), Italian University Line (IT), Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli (IT), LUM Jean Monnet University (IT), Hospital Universitario Ramón y Cajal (ES), University of Córdoba (ES)
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon